| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Transliterated Title: 可切除的局部进展期胃癌及转移性胃癌治疗现状及进展.
- Publication Type: Journal Article
- Language: English; Chinese
- [Zhong Nan Da Xue Xue Bao Yi Xue Ban] 2020 Apr 28; Vol. 45 (4), pp. 426-434.
- MeSH Terms: Splenic Neoplasms* ; Stomach Neoplasms / *drug therapy ; Antineoplastic Combined Chemotherapy Protocols ; Gastrectomy ; Humans ; Neoadjuvant Therapy
- References: Liu H, Kinoshita T, Tonouchi A, et al. What are the reasons for a longer operation time in robotic gastrectomy than in laparoscopic gastrectomy for stomach cancer?[J]. Surg Endosc, 2019, 33(1): 192- 198. ; Xiao H, Liu W, Quan H, et al. Peri-operative blood transfusion does not influence overall and disease-free survival after radical gastrectomy for Stage II/III gastric cancer: A propensity score matching analysis[J]. J Gastrointest Surg, 2018, 22(9): 1489- 1500. ; Reddavid R, Sofia S, Chiaro P, et al. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake?[J]. World J Gastroenterol, 2018, 24(2): 274- 289. ; Jia F, Teer JK, Knepper TC, et al. Discordance of somatic mutations between asian and caucasian patient populations with gastric cancer[J]. Mol Diagn Ther, 2017, 21(2): 179- 185. ; Li R, Leng AM, Liu T, et al. Weekday of surgery affects postoperative complications and long-term survival of Chinese gastric cancer patients after curative gastrectomy[J]. Biomed Res Int, 2017, 2017: 1- 11. ; Cai J, Wei D, Gao CF, et al. A prospective randomized study comparing open versus laparoscopy-assisted D2 radical gastrectomy in advanced gastric cancer[J]. Dig Surg, 2011, 28(5/6): 331- 337. ; Lee JH, Son SY, Lee CM, et al. Morbidity and mortality after laparoscopic gastrectomy for advanced gastric cancer: results of a phase II clinical trial[J]. Surg Endosc, 2013, 27(8): 2877- 2885. ; Inaki N, Etoh T, Ohyama T, et al. A multi-institutional, prospective, phase II feasibility study of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for locally advanced gastric cancer (JLSSG0901)[J]. World J Surg, 2015, 39(11): 2734- 2741. ; Hu Y, Huang C, Sun Y, et al. Morbidity and mortality of laparoscopic versus open D2 distal gastrectomy for advanced gastric cancer: A randomized controlled trial[J]. J Clin Oncol, 2016, 34(12): 1350- 1357. ; Hur H, Lee HY, Lee HJ, et al. Efficacy of laparoscopic subtotal gastrectomy with D2 lymphadenectomy for locally advanced gastric cancer: the protocol of the KLASS-02 multicenter randomized controlled clinical trial[J]. BMC cancer, 2015, 15(1): 355. ; Strong VE. Gastric cancer: principles and practice[M]. Switzerland: Springer International Publishing, 2015: 186. ; Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D 1 and D 2 resections for gastric cancer: long-term results of the MRC randomized surgical trial[J]. Br J Cancer, 1999, 79(9/10): 1522- 1530. ; Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer[J]. N Engl J Med, 1999, 340(12): 908- 914. ; Wu CW, Chao AH, Lo SS, et al. Nodal dissection for patients with gastric cancer: A randomised controlled trial[J]. Lancet Oncol, 2006, 7(4): 309- 315. ; Kunisaki C, Akiyama H, Nomura M, et al. Comparison of surgical results of D2 versus D3 gastrectomy (para-aortic lymph node dissection) for advanced gastric carcinoma: A multi-institutional study[J]. Ann Surg Oncol, 2006, 13(5): 659- 667. ; Yonemura Y, Wu CC, Fukushima N, et al. Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer[J]. Int J Clin Oncol, 2008, 13(2): 132- 137. ; Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer[J]. N Engl J Med, 2008, 359(5): 453- 462. ; Hu JK, Yang K, Bo Z, et al. D2 plus para-aortic lymphadenectomy versus standardized D2 lymphadenectomy in gastric cancer surgery[J]. Surg Today, 2009, 39(3): 207- 213. ; Fujimura T, Nakamura K, Oyama K, et al. Selective lymphadenectomy of para-aortic lymph nodes for advanced gastric cancer[J]. Oncol Rep, 2009, 22(3): 509. ; Morita S, Fukagawa T, Fujiwara H, et al. The clinical significance of para-aortic nodal dissection for advanced gastric cancer[J]. Eur J Surg Oncol, 2016, 42(9): 1448- 1454. ; Wang W, Yi XJ, Wan J. Clinical significance of para-aortic lymph node dissection in gastric cancer[J]. Chin J Gen Surg, 2018, 27(4): 391- 395. ; Yoshikawa T, Sasako M, Yamamoto S, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer[J]. Br J Surg, 2009, 96(9): 1015- 1022. ; Oyama K, Fushida S, Kinoshita J, et al. Efficacy of pre-operative chemotherapy with docetaxel, cisplatin, and S-1 (DCS therapy) and curative resection for gastric cancer with pathologically positive para-aortic lymph nodes[J]. J Surg Oncol, 2012, 105(6): 535- 541. ; Tsuburaya A, Mizusawa J, Tanaka Y, et al. Neoadjuvant chemotherapy with S‐1 and cisplatin followed by D2 gas-trectomy with para‐aortic lymph node dissection for gastric cancer with extensive lymph node metastasis[J]. Br J Surg, 2014, 101(6): 653- 660. ; Wang Y, Yu YY, Li W, et al. A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis[J]. Cancer Chemother Pharmacol, 2014, 73(6): 1155- 1161. ; Zhang ZX, Gu XZ, Yin WB, et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)―report on 370 patients[J]. Int J Radiat Oncol Biol Phys, 1998, 42(5): 929- 934. ; Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction[J]. J Clin Oncol, 2009, 27(6): 851- 856. ; Shapiro J, van Lanschot JJB, MCCM Hulshof, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial[J]. Lancet Oncol, 2015, 16(9): 1090- 1098. ; Klevebro F, Alexandersson von Döbeln G, Wang N, et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction[J]. Ann Oncol, 2016, 27 (4): 660- 667. ; Macdonald JS, Smalley SR, Benedetti J, et al. Chemo-radiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction[J]. N Engl J Med, 2001, 345(10): 725- 730. ; Park SH, Sohn TS, Lee J, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: Final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses[J]. J Clin Oncol, 2015, 33(28): 3130- 3136. ; Cats A, Jansen EPM, van Grieken NCT, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): An international, open-label, randomised phase 3 trial[J]. Lancet Oncol, 2018, 19(5): 616- 628. ; Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med, 2006, 355: 11- 20. ; Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial[J]. J Clin Oncol, 2011, 29(13): 1715- 1721. ; Li ZY, Koh CE, Bu ZD, et al. Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer[J]. J Surg Oncol, 2012, 105(8): 793- 799. ; Messager M, Lefevre JH, Pichotdelahaye V, et al. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study[J]. Ann Surg, 2011, 254(5): 684- 693. ; Bringeland EA, Wasmuth HH, Fougner R, et al. Impact of perioperative chemotherapy on oncological outcomes after gastric cancer surgery[J]. Br J Surg, 2014, 101(13): 1712- 1720. ; Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data[J]. Eur J Cancer, 2013, 49(15): 3149- 3158. ; Yang Y, Yin X, Sheng L, et al. Perioperative chemotherapy more of a benefit for overall survival than adjuvant chemotherapy for operable gastric cancer: an updated Meta-analysis[J]. Sci Rep, 2015, 5: 12850. ; Zhao J, Gao P, Song Y, et al. Which is better for gastric cancer patients, perioperative or adjuvant chemotherapy: A Meta-analysis[J]. Bmc Cancer, 2016, 16(1): 631. ; Coccolini F, Nardi M, Montori G, et al. Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials[J]. Int Journal Surg, 2018, 51: 120- 127. ; Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in Stage II or III gastric cancer[J]. J Clin Oncol, 2011, 29(33): 4387- 4393. ; Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial[J]. Lancet, 2012, 379(9813): 315- 321. ; Chang YR, Han DS, Kong SH, et al. The value of palliative gastrectomy in gastric cancer with distant metastasis[J]. Ann Surg Oncol, 2012, 19(4): 1231- 1239. ; Warschkow R, Baechtold M, Leung K, et al. Selective survival advantage associated with primary tumor resection for metastatic gastric cancer in a Western population[J]. Gastric Cancer, 2018, 21(2): 324- 337. ; Saidi RF, ReMine SG, Dudrick PS. Is there a role for palliative gastrectomy in patients with Stage IV gastric cancer?[J]. World J Surg, 2006, 30(1): 21- 27. ; Chang YR, Han DS, Kong SH, et al. The value of palliative gastrectomy in gastric cancer with distant metastasis[J]. Ann Surg Oncol, 2012, 19(4): 1231- 1239. ; Dong Y, Ma S, Yang S, et al. Non-curative surgery for patients with gastric cancer with local peritoneal metastasis: A retrospective cohort study[J]. Medicine, 2016, 95(49): e5607. ; Hsu JT, Liao JA, Chuang HC, et al. Palliative gastrectomy is beneficial in selected cases of metastatic gastric cancer[J]. BMC Palliat Care, 2017, 16(1): 19. ; Warschkow R, Baechtold M, Leung K, et al. Selective survival advantage associated with primary tumor resection for metastatic gastric cancer in a Western population[J]. Gastric Cancer, 2018, 21(2): 324- 337. ; Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): A phase 3, randomised controlled trial[J]. Lancet Oncol, 2016, 17(3): 309- 318. ; Kerkar SP, Kemp CD, Duffy A, et al. The GYMSSA trial: A prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone[J]. Trials, 2009, 10(1): 121. ; Al-Batran SE, Goetze TO, Mueller DW, et al. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction―A phase III trial of the German AIO/CAO-V/CAOGI[J]. BMC cancer, 2017, 17(1): 893. ; Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: A French intergroup study[J]. J Clin Oncol, 2014, 32(31): 3520- 3526. ; Wang Y, Zhuang RY, Yu YY, et al. Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX)[J]. Oncotarget, 2016, 7(46): 76298- 76307. ; Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopatho-logical regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adeno-carcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial[J]. Lancet Oncol, 2016, 17(12): 1697- 1708. ; Fuchs CS, Niedzwiecki D, Mamon HJ, et al. Adjuvant chemoradiotherapy with epirubicin, cisplatin, and fluorouracil compared with adjuvant chemoradiotherapy with fluorouracil and leucovorin after curative resection of gastric cancer: Results from CALGB 80101 (Alliance)[J]. J Clin Oncol, 2017, 35(32): 3671- 3677. ; Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial[J]. J Clin Oncol, 2013, 31(35): 4438- 4444. ; Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group[J]. J Clin Oncol, 2006, 24(31): 4991- 4997. ; van Cutsem E, Boni C, Tabernero J, et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study[J]. Ann Oncol, 2015, 26(1): 149- 156. ; Kim HS, Ryu MH, Zang DY, et al. Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11[J]. Gastric cancer, 2018, 21(5): 802- 810. ; Bajetta E, Floriani I, di Bartolomeo M, et al. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer[J]. Ann Oncol, 2014, 25(7): 1373- 1378. ; van Cutsem E, Bang YJ, Feng FY, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer[J]. Gastric cancer, 2015, 18(3): 476- 484. ; Gomez-Martin C, Plaza JC, Pazo-Cid R, et al. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab[J]. J Clin Oncol, 2013, 31(35): 4445- 4452. ; Bang YJ, van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742): 687- 697. ; Tabernero J, Hoff PM, Shen L, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): Final analysis of a double-blind, randomised, placebo-controlled phase 3 study[J]. Lancet Oncol, 2018, 19(10): 1372- 1384. ; Satoh T, Xu RH, Chung HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN―a randomized, phase III study[J]. J Clin Oncol, 2014, 32(19): 2039- 2049. ; Shah MA, Xu RH, Bang YJ, et al. HELOISE: Phase IIIb randomized multicenter study comparing standard-of-care and higher-dose Trastuzumab regimens combined with chemo-therapy as first-line therapy in patients with human epidermal growth factor receptor 2-positive metastatic gastric or gastroesophageal junction adenocarcinoma[J]. J Clin Oncol, 2017, 35(22): 2558- 2567. ; Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): An inter-national randomised, open-label, adaptive, phase 2/3 study[J]. Lancet Oncol, 2017, 18(5): 640- 653. ; Kataoka K, Tokunaga M, Mizusawa J, et al. A randomized phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan clinical oncology group study JCOG1301 (Trigger Study)[J]. Jpn J Clin Oncol, 2015, 45(11): 1082- 1086. ; Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial[J]. Lancet, 2014, 383(9911): 31- 39. ; Wilke H, Muro K, van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(11): 1224- 1235. ; Yoon HH, Bendell JC, Braiteh FS, et al. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adeno-carcinoma: a randomized, double-blind, multicenter phase II trial[J]. Ann oncol, 2016, 27(12): 2196- 2203. ; Ohtsu A, Shah MA, van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study[J]. J Clin Oncol, 2011, 29(30): 3968- 3976. ; Sawaki A, Yamada Y, Yamaguchi K, et al. Regional differences in advanced gastric cancer: Exploratory analyses of the AVAGAST placebo arm[J]. Gastric Cancer, 2018, 21(3): 429- 438. ; Shen L, Li J, Xu J, et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)[J]. Gastric Cancer, 2015, 18(1): 168- 176. ; Cunningham D, Stenning SP, Smyth EC, et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial[J]. Lancet Oncol, 2017, 18(3): 357- 370. ; Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adeno-carcinoma of the stomach or gastroesophageal junction[J]. J Clin Oncol, 2016, 34(13): 1448- 1454. ; Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refrac-tory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 390(10111): 2461- 2471. ; Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2018, 392(10142): 123- 133. ; Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: Final results of a phase III randomized clinical trial[J]. Ann Surg Oncol, 2011, 18(6): 1575- 1581. ; Rudloff U, Langan RC, Mullinax JE, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial[J]. J Surg Oncol, 2014, 110(3): 275- 284. ; Magge D, Zenati M, Mavanur A, et al. Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis[J]. Ann Surg Oncol, 2014, 21(5): 1448- 1455. ; Müller H, Hotopp T, Tofeili A. Systemic chemotherapy using FLOT-regimen combined with cytoreductive surgery plus HIPEC for treatment of peritoneal metastasized gastric cancer [J]. Hepatogastroenterology, 2014, 61(131): 703- 706. ; Topal B, Demey K, Topal H, et al. Cytoreductive surgery and hyperthermic intra-operative peritoneal chemotherapy with Cisplatin for gastric peritoneal carcinomatosis monocentric phase-2 nonrandomized prospective clinical trial[J]. BMC Cancer, 2017, 17(1): 771. ; Yang XW, Zhu SH, Li PZ, et al. Outcomes of laparoscopic gastrectomy for gastric cancer in elderly patients[J]. J BUON, 2018, 23(1): 85- 91. ; Liao P, Jia F, Teer JK, et al. Geographic variation in molecular subtype for gastric adenocarcinoma[J]. Gut, 2019, 68(7): 1340- 1341.
- Grant Information: 2014SK2012 the Key Projects of Science and Technology Department of Hunan Province, China
- Contributed Indexing: Keywords: advanced gastric cancer; metastatic gastric cancer; progressive gastric cancer ; Local Abstract: [Publisher, Chinese] 对于可切除胃癌而言，根治性手术仍然作为治疗的核心手段，但对于转移性胃癌而言，手术方式的选择和手术效果需要探索。放射治疗(以下简称放疗)、化学治疗(以下简称化疗)、分子靶向治疗在延长胃癌患者生存期中发挥了重要的作用，术后放疗、化疗可以延长生存期，对于局部晚期的胃癌患者，术前行放疗、化疗相比于直接手术，亦能进一步延长患者的生存期。另外，随着分子靶向药物(如抗血管生成药物、免疫抑制药物等)的研发和使用，胃癌患者的生存期可进一步延长。.
- Entry Date(s): Date Created: 20200904 Date Completed: 20200924 Latest Revision: 20200924
- Update Code: 20240513
|
